Nuvilex (NASDAQ:PMCB) Trading Down 3.3% – Time to Sell?

Nuvilex Inc. (NASDAQ:PMCB) was down 3.3% during trading on Wednesday . The stock traded as low as $0.76 and last traded at $0.76. Approximately 79,050 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 298,982 shares. The stock had previously closed at $0.7856.

Analysts Set New Price Targets

Several research analysts have recently commented on PMCB shares. Wall Street Zen raised Nuvilex to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Nuvilex presently has an average rating of “Sell”.

Nuvilex Stock Performance

The stock has a fifty day moving average of $0.74 and a 200 day moving average of $0.78. The company has a market capitalization of $8.16 million, a PE ratio of -0.68 and a beta of 0.46.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.